Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

Hu, Jiao; Chen, Jinbo; Ou, Zhenyu; Chen, Haige; Liu, Zheng; Chen, Minfeng; Zhang, Ruiyun; Yu, Anze; Cao, Rui; Zhang, Enchong; Guo, Xi; Peng, Bo; Deng, Dingshan; Cheng, Chunliang; Liu, Jinhui; Li, Huihuang; Zou, Yihua; Deng, Ruoping; Qin, Gang; Li, Wenze; Wang, Lue; Chen, Tao; Pei, Xiaming; Gong, Guanghui; Tang, Jiansheng; Othmane, Belaydi; Cai, Zhiyong; Zhang, Chunyu; Liu, Zhi; Zu, Xiongbing

doi:10.1016/j.xcrm.2022.100785

Public

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

Published in Cell Reports Medicine • Oct 19, 2022

Authors:

Jiao Hu

Jinbo Chen

Zhenyu Ou

Abstract

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi...

Subject

Medicine

Neoadjuvant therapy

Bladder cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!